Elicio TherapeuticsELTX
ELTX
About: Elicio Therapeutics Inc is a clinical-stage biotechnology company pioneering the development of cancer immunotherapies for patients with limited treatment options and poor outcomes. Its proprietary Amphiphile, or AMP, platform delivers investigational immunotherapeutics directly to the brain center of the immune system the lymph nodes. Its focus is the development of cancer immunotherapies against biologically validated but hard-to-drug targets that can be activated through lymph node trafficking.
Employees: 26
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
350% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 2
335% more capital invested
Capital invested by funds: $2.25M [Q4 2024] → $9.8M (+$7.55M) [Q1 2025]
300% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 2
41% more funds holding
Funds holding: 17 [Q4 2024] → 24 (+7) [Q1 2025]
5.83% more ownership
Funds ownership: 4.21% [Q4 2024] → 10.04% (+5.83%) [Q1 2025]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$10
32%
upside
Avg. target
$10
32%
upside
High target
$10
32%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Robert Burns | 32%upside $10 | Buy Reiterated | 2 Apr 2025 |
Financial journalist opinion
Neutral
GlobeNewsWire
1 week ago
Elicio Therapeutics Secures $10 Million in Financing
Funding expected to support operations into Q1 2026. Anticipated AMPLIFY-7P Phase 2 interim analysis expected in Q3 2025.
Neutral
GlobeNewsWire
1 month ago
Elicio Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Updates
Interim analysis focused on disease-free survival (“DFS”) in randomized Phase 2 AMPLIFY-7P clinical trial expected in Q3 2025
Positive
Zacks Investment Research
1 month ago
Here's Why Elicio Therapeutics (ELTX) Could be Great Choice for a Bottom Fisher
Elicio Therapeutics (ELTX) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Neutral
GlobeNewsWire
1 month ago
Elicio Therapeutics Reports Inducement Grant to New Chief Strategy and Financial Officer and Other New Hires
BOSTON, April 16, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that on April 15, 2025, Elicio granted inducement awards to Elicio's newly appointed Chief Strategy and Financial Officer, Preetam Shah, and two additional new employees, as an inducement material to Dr. Shah and such employees entering into employment with Elicio in accordance with Nasdaq Listing Rule 5635(c)(4), which grants were approved by the compensation committee of Elicio's board of directors in accordance with the Elicio 2024 Inducement Incentive Award Plan.
Positive
Zacks Investment Research
2 months ago
Is Elicio Therapeutics, Inc. (ELTX) Stock Outpacing Its Medical Peers This Year?
Here is how Elicio Therapeutics (ELTX) and Inventiva S.A. Sponsored ADR (IVA) have performed compared to their sector so far this year.
Positive
Zacks Investment Research
2 months ago
Elicio Therapeutics (ELTX) Upgraded to Buy: Here's What You Should Know
Elicio Therapeutics (ELTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Neutral
GlobeNewsWire
2 months ago
Elicio Therapeutics Reports 2024 Financial Results and Provides Corporate Updates
Completed enrollment of Phase 2 AMPLIFY-7P randomized study; disease-free survival (“DFS”) event-driven interim analysis expected in Q3 2025
Neutral
GlobeNewsWire
2 months ago
Elicio Therapeutics Appoints Preetam Shah, Ph.D., MBA, as Chief Strategy and Financial Officer
BOSTON, March 24, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced the appointment of Preetam Shah, Ph.D., MBA, as Chief Strategy and Financial Officer, effective as of the date hereof.
Positive
Seeking Alpha
4 months ago
Elicio: Lymph Node Binding With ELI-002 Could Lead To Substantial 1st Half 2025 Data
Interim analysis from the phase 1/2 AMPLIFY-7P study, using ELI-002 for the treatment of KRAS mutant pancreatic cancer patients, is expected in the 1st half of 2025. The global pancreatic cancer market size is expected to reach $7.4 billion by 2032; It is said that approximately 88% of PDAC cases deal with the KRAS mutation. The company has already established a proposed phase 3 design with the FDA in a Type B meeting using ELI-002 for the treatment of patients with KRAS-mutant pancreatic cancer.
Neutral
GlobeNewsWire
4 months ago
Elicio Therapeutics Reaches Alignment with FDA on ELI-002 Registrational Strategy
Received supportive FDA feedback on key elements of the potential ELI-002 Phase 3 study design, including dose, schedule, patient population and primary endpoint analysis
Charts implemented using Lightweight Charts™